EP 0956352 A1 19991117 - A POLYNUCLEOTIDE HERPES VIRUS VACCINE
Title (en)
A POLYNUCLEOTIDE HERPES VIRUS VACCINE
Title (de)
EIN POLYNUKLEOTID ENTHALTENDER HERPES VIRUS IMPFSTOFF
Title (fr)
VACCINS DE POLYNUCLEOTIDES CONTRE LE VIRUS DE L'HERPES
Publication
Application
Priority
- US 9717262 W 19970926
- US 72075896 A 19961001
Abstract (en)
[origin: WO9814586A1] Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of 0.5 mu g of (one) PNV, gave >90 % seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and/or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 31/711 (2006.01); A61K 39/245 (2006.01); A61K 48/00 (2006.01); A61P 31/22 (2006.01); C07K 14/035 (2006.01); C12N 15/38 (2006.01)
CPC (source: EP)
A61P 31/22 (2017.12); C07K 14/005 (2013.01); A61K 2039/51 (2013.01); C12N 2710/16622 (2013.01)
Citation (search report)
See references of WO 9814586A1
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9814586 A1 19980409; CA 2267645 A1 19980409; EP 0956352 A1 19991117; JP 2001501101 A 20010130
DOCDB simple family (application)
US 9717262 W 19970926; CA 2267645 A 19970926; EP 97944467 A 19970926; JP 51667398 A 19970926